Imraldi
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Imraldi, covering 2021-04-27 to 2026-02-04. Get the full timeline:
Most recent: EMA Authorised: Imraldi (adalimumab) — Samsung Bioepis NL B.V.
2 regulatory and trial events tracked for Imraldi, covering 2021-04-27 to 2026-02-04. Get the full timeline:
Most recent: EMA Authorised: Imraldi (adalimumab) — Samsung Bioepis NL B.V.